Summarized by Masters of Longevity from Longevity Technology.
A preview of a news article about preclinical mouse research on a mitochondrial-targeted obesity drug that shifts cellular fuel use; it guides readers on what to expect from the conference presentation and why the study angle is noteworthy.
Key Takeaways
- MitoRx will present mouse data showing MTRX31 shifts metabolism from fat to carbohydrate oxidation and induces weight loss.
- In diet-induced obesity mice MTRX31 reduced body weight and fat mass while preserving lean mass compared with controls.
- MitoRx reports greater and more durable weight loss than tirzepatide at the doses evaluated in their preclinical study.
